#USA #Abbott #Abbott Park #Colorectal Cancer #Oncodetect

Abbott's Groundbreaking Oncodetect® Test for Colorectal Cancer

Abbott, a leader in the healthcare industry, has recently showcased significant advancements in colorectal cancer monitoring with its Oncodetect® test at the European Society for Medical Oncology (ESMO) Congress. New data reveals that the whole-genome sequencing (WGS) Oncodetect test demonstrates a remarkable 30% absolute improvement in sensitivity, enhancing the detection of residual disease following surgery.

Understanding the Challenge of Residual Disease

For colorectal cancer patients, while surgical intervention can successfully remove visible tumors, a significant challenge remains: detecting minute traces of cancer that may still linger post-operation. A pioneering study named Beta-CORRECT, conducted in collaboration with renowned oncologist Dr. Takayuki Yoshino from the National Cancer Center Hospital East in Japan, sought to address this critical issue. The test now tracks up to 5,000 unique DNA variants, which significantly expands the detection capability for residual disease even when only minimal fragments of cancer DNA are present.

This study, the first clinical validation of the WGS Oncodetect test in patients with varying stages of colorectal cancer, has been presented as a pivotal step forward in the landscape of oncology diagnostics. Involving post-surgical samples from 279 patients primarily diagnosed with stages II and III colorectal cancer, the findings aim to transform patient management and improve outcomes.

Key Findings from the Beta-CORRECT Study

The study's results underscore the enhanced accuracy of the WGS Oncodetect test:

• - Sensational Improvement: A single blood test conducted approximately a month post-surgery using the WGS test achieved a sensitivity of 72.2% for detecting cancer recurrence within two years, a significant jump from the 42.2% sensitivity recorded by the previous whole-exome sequencing (WES) test. This 30% improvement in detection highlights the WGS test's superior capability in monitoring colorectal cancer.

• - Enhanced ctDNA Detection: Among the 157 patients assessed using both tests, the WGS method identified circulating tumor DNA (ctDNA) in all 29 patients flagged by the WES test, plus an additional 15 patients. Notably, many of these detections occurred at levels beneath 20 parts per million (ppm), indicating an ability to identify residual disease at extremely low concentrations.

• - Striking Prognostic Significance: Patients who displayed detectable ctDNA post-surgery exhibited a staggering 10.6 times greater risk of cancer recurrence than those without detectable ctDNA. Furthermore, the data revealed stark differences in two-year disease-free survival rates: only 36.2% for ctDNA-positive patients versus 92.3% for those who were ctDNA-negative.

• - Particular Insights for Stage II Patients: The study found that those with detectable ctDNA after surgery faced an approximately 31-fold higher recurrence risk compared to ctDNA-negative individuals, illuminating the critical need for sensitive monitoring in this patient cohort.

The Importance of Sensitivity in MRD Testing

Dr. Rick Baehner, divisional vice president and chief medical officer of Abbott's cancer diagnostics business, emphasized the implications of these findings, stating, "The ability to identify additional patients with detectable ctDNA after surgery may refine our assessment of recurrence risk beyond traditional clinical evaluations."

These revelations provide crucial insights into cancer recurrence dynamics, reinforcing the importance of sensitivity in molecular residual disease (MRD) testing. The identification of ctDNA has emerged as the strongest predictor of recurrence, prompting further investigations into its relationship with clinical outcomes and adjuvant therapies.

Conclusion and Future Directions

Abbott’s commitment to improving colorectal cancer screening and monitoring through its innovative technologies remains steadfast. With advancements like the Oncodetect test, the promise of more personalized oncology care moves closer to reality, empowering clinicians with the tools necessary for informed decision-making. Continued research will pave the way for enhanced patient management strategies, ultimately aiming to transform the trajectory of colorectal cancer care.

For more information about the Oncodetect test and Abbott’s groundbreaking contributions to cancer diagnostics, visit Abbott's official website.